| Patient and physician perceptions about blood transfusions in the myelodysplastic syndromes |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Real-world impact of luspatercept on red blood cell transfusions among patients with myelodysplastic syndromes: A United States healthcare claims database study |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS) |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents |
|
Leukemia Research |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Following in the footsteps of acute myeloid leukemia: are we witnessing the start of a therapeutic revolution for higher-risk myelodysplastic syndromes? |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Raising the bar for lower-risk myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
